44 results about "Intestinal adhesions" patented technology

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The present invention relates to the technical field of the development and utilization of probiotics, specifically to a Weissella confusa DY12 with probiotic activity and its application. The Weissella confusa DY12 was isolated from sheep feces. The present invention identified the probiotic effect of Weissella confusa DY12 through animal experiments. The results showed that Weissella confusa DY12 could tolerate acid and bile salts and resist the gastrointestinal internal environment; its hydrophobicity was 39.47% and its auto-aggregation was 48.12%, demonstrating that the Weissella confusa DY12 of the present invention has good intestinal adhesion ability and has the potential of probiotics. The present invention verified that Weissella confusa DY12 can effectively regulate the immune function of the animal body, improve the antioxidant capacity of the body, as well as the content of lysozyme and the activity of alkaline phosphatase, and increase the daily weight gain, ultimately improving the growth performance of animals.

The present invention belongs to the field of biomedicine technology, and specifically relates to a strain of Lactobacillus plantarum YYY01 and its application in anti-inflammatory and production of γ-aminobutyric acid. The Lactobacillus plantarum YYY01 provided by the present invention is deposited with GDMCC NO: 65147. The Lactobacillus plantarum YYY01 has good biosafety, survives well in the gastrointestinal environment and has a certain intestinal adhesion ability; Lactobacillus plantarum YYY01 can produce high γ-aminobutyric acid, has anti-inflammatory, intestinal flora regulation and immune barrier enhancement effects. It shows good application prospects in increasing the yield of γ-aminobutyric acid and preparing products containing γ-aminobutyric acid.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

This invention provides a *Lactobacillus plantarum* LN-Lp1 strain, its applications, products, and methods, belonging to the field of probiotic technology. The *Lactobacillus plantarum* LN-Lp1 strain has the accession number CGMCC 33158. This LN-Lp1 strain was deposited on December 23, 2024, at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing. Based on this strain, this invention also provides its uses and related products. This LN-Lp1 strain exhibits strong resistance to simulated gastric-intestinal stress and good intestinal adhesion and colonization potential. The *Lactobacillus plantarum* LN-Lp1 of this invention has excellent weight-loss effects, improving lipid metabolism and lowering blood lipid levels.

The invention relates to the field of microorganisms, in particular to kitten source pediococcus pentosaceus JZ01 and application thereof. The kitten source pediococcus pentosaceus JZ01 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 19, 2024, and the preservation number is CGMCC NO.31002. The kitten source pediococcus pentosaceus JZ01 has the advantages that the kitten source pediococcus pentosaceus JZ01 is The kitten source pediococcus pentosaceus JZ01 disclosed by the invention has relatively strong acid resistance, bile salt resistance and extremely strong intestinal adhesion capacity, has a good inhibition effect on common pathogenic bacteria, is sensitive to various antibiotics and has good probiotic potential, a new candidate strain is provided for pet food, health-care treatment products or probiotic preparations, and the kitten source pediococcus pentosaceus JZ01 has a good application prospect. Wide application prospects are realized in the aspects of preparing pet foods, health care products, medicines and the like.

The present invention discloses Lactobacillus kefiranofaciens IMAU12319 and its application, belonging to the technical field of microorganisms, and particularly relates to Lactobacillus kefiranofaciens ( Lactobacillus kefiranofaciens ) IMAU12319, which was deposited on July 8, 2024 at the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, with the deposit address being No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the accession number being: CGMCC No. 31224. The application of Lactobacillus kefiranofaciens IMAU12319 in the preparation of probiotic agents resistant to gastrointestinal digestion. The bacterium of the present invention not only exhibits good gastrointestinal tolerance ability, but also shows strong potential in intestinal adhesion, antioxidant and antibacterial aspects, and has broad application prospects in starter cultures.

The present disclosure can improve the degree of soy protein proteolysis and the ability to produce valine, isoleucine, and leucine, which are branched-chain amino acids, as well as other amino acids, such as threonine, glycine, tyrosine, and lysine. Accordingly, the present disclosure can prevent sarcopenia and has antioxidant activity. Also, the present disclosure can maintain protein metabolic balance and relieve sarcopenia by muscle synthesis.The self-aggregation, hydrophobicity, and intestinal adhesion of a mixed strain is improved compared to a case where a single strain used for the mixed strain is used. Therefore, when the mixed strain of the present disclosure is ingested, the strain can remain for a long time in the intestine.

A preparation method of the methacrylated gelatin with the dual functions comprises the following steps: firstly, preparing collagen methylated polymethacrylate, then mixing 5% of collagen methylated polymethacrylate, 0.2% of trimethylbenzoyl phosphonate, 10 mg / ml of a herba houttuyniae extract and 20 micrograms / ml of nifedimab, and carrying out uniform mixing, so as to obtain the methacrylated gelatin with the dual functions, the collagen methylated polymethacrylate and the trimethylbenzoyl phosphonate, the herba houttuyniae extract, the nifedimab and the collagen methylated polymethacrylate, the herba houttuyniae extract and the nifedimab. The methacrylated gelatin is prepared under ultraviolet irradiation, and the loose cross-linked network structure of the methacrylated gelatin can realize continuous release of drugs, so that the demand of continuous and stable drug delivery is met; in addition, the gelatin methacrylamide, the herba houttuyniae extract and the nintedanib are combined to relieve hemorrhagic intestinal adhesion and can regulate inflammation and anti-fibrosis functions.

To provide an intestinal disorder controlling agent, an antiallergic agent, an immunopotentiator and an intestinal adhesion improver of lactic acid bacteria, safely ingestible, inexpensively available and excellent in intestinal adhesion improving action of lactic acid bacteria.SOLUTION: The agent of the present invention contains a flower extract. The flower is a flower of Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae, and is particularly preferably at least one selected from the group consisting of safflower, pomegranate, kudzu, cherry, chrysanthemum, saffron, peach and rose.SELECTED DRAWING: Figure 1

The invention provides a small intestine stoma enteral nutrition feeding device, system and method, and the device comprises a feeding device body which is in a nipple shape, and the bottom of the feeding device body is provided with at least one nutrient solution outlet; the fixing assembly is arranged on the feeding device body and used for fixing the feeding device body to the small intestine stoma; the nutrient solution conveying assembly is arranged on the feeding device body and used for conveying the nutrient solution to the nutrient solution outlet from the outside. According to the feeding device, firstly, the feeding device body is placed at the stoma of the small intestine and stably fixed through the fixing assembly, and therefore enteral nutrition backflow caused by device moving or falling off in the feeding process is avoided. Through the nutrient solution conveying assembly, the conveying speed and amount of the nutrient solution can be accurately controlled, it is ensured that the patient obtains a proper amount of nutrient support, and the situation that the patient absorbs nutrition poorly due to abdominal cavity infection, intestinal adhesion and other problems in the operation is prevented.

The invention relates to a traditional Chinese medicine composition for treating postoperative intestinal adhesion. The traditional Chinese medicine composition is applied to preparation of a medicine for treating postoperative intestinal adhesion. The traditional Chinese medicine composition is prepared from, by weight, 7-11 parts of peach kernels, 7-11 parts of safflower carthamus, 13-17 parts of prepared rehmannia roots, 7-11 parts of angelica sinensis, 7-11 parts of radix paeoniae alba, 7-11 parts of ligusticum wallichii, 7-11 parts of radix aucklandiae and 4-8 parts of betel nuts. The traditional Chinese medicine composition is proper in compatibility, can promote blood circulation to remove blood stasis, promote qi circulation to remove stagnation, nourish blood to relax bowels, remove blood stasis, smooth qi activity and promote new blood circulation, and is beneficial to diminishing inflammation and absorbing adhesion. Along with continuous and deep research on the symptoms of the disease, the traditional Chinese medicine composition is often used for various symptoms caused by qi stagnation and blood stasis according to the effects of promoting blood circulation to remove blood stasis and promoting qi circulation to relieve pain, and good effects are achieved.

The invention provides antibacterial peptide-berberine co-assembled hydrogel and application thereof in preparation of anti-infection drugs, lauric acid is connected to the N terminal and the C terminal of antibacterial peptide KKWWW for amidation to obtain antibacterial peptide 2KW, then BBR is added, and the antibacterial peptide 2KW and the antibacterial peptide 2KW are co-assembled through hydrophobic interaction and hydrogen-bond interaction to form the hydrogel, namely 2KW-BBR. The 2KW-BBR hydrogel can perfectly fit and completely cover the damaged surface of the peritoneum by virtue of the unique physical characteristics of the 2KW-BBR hydrogel, and the effective isolation of the 2KW-BBR hydrogel from surrounding tissues is realized by virtue of a compact net structure in the 2KW-BBR hydrogel. Compared with traditional antibiotics such as polymyxin B, severe pulmonary toxicity risks are often accompanied in the treatment process, and 2KW-BBR shows extremely low toxicity characteristics, so that the traditional antibiotics have higher safety and wider application range. In addition, due to the excellent antibacterial ability, the polypeptide can be used for preparing drugs for treating wound infection caused by MRSA or resisting postoperative intestinal adhesion, and has wide application prospects in clinical research and development of anti-infection drugs.

The present application relates to a kind of traditional Chinese medicine composition for treating postoperative intestinal adhesion, the application of traditional Chinese medicine composition in preparing the drug for treating postoperative intestinal adhesion The traditional Chinese medicine composition is made of the following weight parts of raw medicinal materials: peach kernel 7-11 parts, safflower 7-11 parts, prepared rehmannia 13-17 parts, angelica 7-11 parts, white peony root 7-11 parts, chuanxiong 7-11 parts, costus 7-11 parts, areca nut 4-8 parts.The present application is properly matched, can promote blood circulation to remove blood stasis, move qi and unblock stagnation, nourish blood and dredge fu organs, make blood stasis go, qi movement is smooth, new blood flows, and it is helpful for the subsidence of inflammation and the absorption of adhesion.With the continuous deepening of the study on the disease syndrome, according to the effect of blood-activating and stasis-removing, qi-moving and pain-relieving of the present application, it is often used for a variety of disease syndromes caused by qi stagnation and blood stasis, and good effect is obtained.

The application discloses a kind of synergistic lycium barbarum polysaccharide-glycoside composite nutritional supplement and preparation method thereof, belong to food nutritional supplement preparation technical field.New fresh Ningxia wolfberry is used as raw material, high-activity lycium barbarum polysaccharide is obtained by enzyme hydrolysis-ultrasonic synergistic extraction, fractional ultrafiltration purification, and target group and crosslinking site are introduced by "click chemistry" strategy;Ginkgo biloba flavonoid glycoside, astragalus saponin and gardenia jasminoides glycoside with specific active conformation are selected, and after being directionally modified by enzyme method, site-specific coupling is carried out with modified lycium barbarum polysaccharide, forming "polysaccharide-glycoside" target coupling compound;After compounding intestinal adhesion type adjuvant and antioxidant protective agent, the finished product is prepared after low-temperature vacuum spray granulation and target modification.The application realizes the double breakthrough of targeted delivery and synergistic effect, the intestinal target enrichment rate is increased by more than 60%, the bioavailability of active ingredient is 90%, the activity retention rate is more than 98% after 6 months of storage, and the antioxidant and immunomodulatory functions are increased by about 2 times compared with traditional products.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating intestinal obstruction and acute pancreatitis and a preparation method and application thereof.The prescription of the traditional Chinese medicine composition comprises 10 + / -1 parts of immature bitter oranges, 10 + / -1 parts of mangnolia officinalis, 20 + / -1 parts of radix aucklandiae, 10 + / -1 parts of radix paeoniae rubra, 10 + / -1 parts of peach kernels, 10 + / -1 parts of salvia miltiorrhiza, 10 + / -1 parts of honeysuckle, 10 + / -1 parts of scutellaria baicalensis, 8 + / -1 parts of fructus cannabis, 10 + / -1 parts of rheum officinale and 15 + / -1 parts of mirabilite. The traditional Chinese medicine composition for treating intestinal obstruction and acute pancreatitis can treat qi stagnation type intestinal obstruction (simple intestinal obstruction), heat accumulation type intestinal obstruction (twisted narrow intestinal obstruction) and blood stasis type intestinal obstruction (intestinal adhesion or neoplastic intestinal obstruction), the treatment range of Dachengqi decoction is expanded, and the curative effect is remarkable; the traditional Chinese medicine can also treat edema type acute pancreatitis.

To provide a medicine for intestinal disorders, an antiallergic agent, an immunoadjuvant and an agent for improving enteroadherent properties of lactic acid bacteria, which can be taken safely, are available inexpensively, and have high effect of improving enteroadherent properties of lactic acid bacteria.SOLUTION: An agent according to the present invention contains flower extract. The flower is a Lythraceae, Asteraceae, Fabaceae, Rosaceae or Iridaceae flower, preferably, at least one selected from Carthamus tinctorius, Punica granatum, Pueraria plants, Subgen. Cerasus plants, Chrysanthemum plants, Crocus sativus, Prunus persica Batsch and Rosa plants.SELECTED DRAWING: Figure 1

The invention relates to an engineering probiotic oral nano capsule modified by a nano material as well as a preparation method and application of the engineering probiotic oral nano capsule. The engineering modification of probiotics comprises the steps of knocking out a clbA gene and overexpressing an Sj16 protein and a GbpA protein. The intestinal adhesion protein GbpA is expressed on the surface of the engineered escherichia coli, an ultrasonic response element is integrated, the immunomodulatory protein Sj16 can be controllably expressed under ultrasonic stimulation, the adhesion and colonization capacity of the engineered escherichia coli in the intestinal tract is enhanced through engineered modification, the immune balance of the intestinal mucosa is cooperatively regulated, and the immunomodulatory effect of the engineered escherichia coli is improved. The generation and secretion of pathogenic autoantibodies from intestinal tracts are obviously reduced. On the basis, the molybdenum-based monatomic nano-material is functionally modified by using an enteric polymer, and a uniform nano-material-polymer composite coating is formed on the modified probiotics by adopting an in-situ wrapping technology, so that the nano-material-polymer composite coating shows a remarkable effect in the aspect of treating the autoimmune nephritis and has an important clinical application value.

The invention relates to the field of microorganisms, in particular to a lactobacillus paracasei subsp. Paracasei GXUN74722 strain and application thereof. The invention provides a strain of Lactobacillus paracasei subsp. Paracasei GXUN74722 and a preparation method thereof. The strain is separated from traditional sour congee in Fusui County of Chongzuo Chongzuo Chongzuo Autonomous District of Guangxi Zhuang, and has good acid production capacity, cholate tolerance and intestinal adhesion capacity. The strain is sensitive to antibiotics such as ampicillin, erythromycin and tetracycline; harmful metabolites such as tyramine, histamine, cadaverine and tryptamine are not generated in the fermentation process; therefore, the strain is relatively high in safety and can be applied to food fermentation. When the strain is inoculated to ferment sour porridge, the fermentation time of the sour porridge can be shortened, the safety of food is improved, and the strain has a good application prospect in the aspect of cereal fermented food.

The present invention belongs to the field of medical technology and specifically relates to a novel medical use of Danbai Granules, particularly the use of Danbai Granules in the preparation of a medicament for treating appendicitis and its complications. The Danbai Granules described herein can significantly inhibit the inflammatory response in rats with HCl-induced appendicitis models and significantly alleviate various symptoms in rabbits with acute appendicitis models. Furthermore, Danbai Granules are a pure traditional Chinese medicine preparation with no toxic side effects, providing a non-invasive treatment that can effectively alleviate patient suffering. They are effective in treating post-operative appendectomy infection, post-operative intestinal adhesions, and chronic appendicitis, opening up a new treatment approach for patients who are intolerant or fearful of surgery, and possessing significant social and economic benefits.

The utility model relates to a kit containing a laparoscopic surgery gauze strip. The kit comprises the gauze strip and a box, the sliver comprises a sliver body, and the sliver body is formed in the mode that two edges of a whole rectangular sliver raw material in the length direction and two edges of the whole rectangular sliver raw material in the width direction are turned inwards and then folded in the width direction. The box comprises a box body and longitudinal and transverse partition plates; and the box body is divided into a plurality of areas for placing slivers by the longitudinal and transverse partition plates. According to the utility model, postoperative peritoneal inflammatory response and intestinal adhesion caused by sliver thread residues left in a body cavity in an operation can be prevented; in addition, storage and counting of the used slivers are facilitated, and the workload of operation nurses and the risk that the slivers are left in the abdominal cavity are reduced.

The application discloses sulfhydrylated oxidized guar gum / sodium alginate microspheres and a preparation method and application thereof, and belongs to the field of biomedical materials. The sulfhydrylated oxidized guar gum and a sodium alginate base material are used to prepare and construct microspheres with pH response, colon targeting and intestinal adhesion by an emulsion gel method, the microsphere technology is used to embed probiotics, and the survival rate of the probiotics in gastric juice is improved. Through in-vitro verification, the method of embedding the microspheres successfully prevents the direct contact of the probiotics with a harsh environment, improves the ability of the probiotics to resist strong acid in the gastrointestinal tract, and enhances the adhesion and colonization effect of the probiotics in the intestinal tract. Through an animal experiment of simulating colitis, the LGG microspheres have the best treatment effect on colitis. Compared with a large number of side effects caused by antibiotic therapy, the treatment method has a certain clinical application prospect as a means with biological safety to treat inflammatory bowel disease.

The invention discloses bifidobacterium-loaded tartary buckwheat protein-sodium alginate compound emulsion gel and a preparation method thereof, and relates to the technical field of emulsion gel preparation. The method comprises the following steps: dissolving a tartary buckwheat protein-sodium alginate compound in a PBS (Phosphate Buffer Solution) to obtain a water phase, then adding an oil phase containing bifidobacterium longum, and shearing and dispersing to obtain an emulsion loaded with bifidobacterium longum; and adding a gelling agent, homogenizing, and standing to obtain the bifidobacterium-loaded tartary buckwheat protein-sodium alginate compound emulsion gel. The delivery system shows excellent performance in the aspects of encapsulation efficiency, dilution resistance, storage stability, thermal protection effect, gastrointestinal tract tolerance and the like by optimizing a preparation process, and a technical support is provided for industrial application of probiotics in the fields of functional foods, medicines and massive health. The problems that in the prior art, bifidobacterium is poor in in-vitro stability, the intestinal survival rate is low after the bifidobacterium is eaten, and the intestinal adhesion rate is low are solved.

The invention relates to the technical field of chewable tablets, and discloses a composite probiotic chewable tablet and a production method thereof, the probiotic chewable tablet comprises the following raw materials: probiotic powder, puerarin-loaded sustained release microspheres, erythritol, isomaltooligosacharide, lemon powder and magnesium stearate; wherein the puerarin-loaded sustained-release microspheres are formed by embedding puerarin through a complex coacervation method, shell layers of the puerarin-loaded sustained-release microspheres are protamine and modified sodium polymannuronate, and after the puerarin-loaded sustained-release microspheres reach the intestinal tract, the intestinal tract adhesion can be realized to achieve the purpose of targeted drug delivery, so that the puerarin can be continuously and slowly released in the intestinal tract; the chewable tablet effectively improves the treatment effect of the chewable tablet on diarrhea, reduces adverse reactions, shortens the cure time, reduces side effects, ensures the safety and reliability of the product, and has a wide market prospect.

The application discloses an EcN@BEVs probiotic compound and a preparation method and application thereof, and belongs to the technical field of biotechnology. The EcN@BEVs probiotic compound comprises Escherichia coli Nissle 1917 EcN and bletilla striata extracellular vesicles BEVs attached to the outer surface of the Escherichia coli Nissle 1917 EcN. The application constructs an advanced targeted delivery system for probiotic preparations, successfully connects the EcN and the BEVs in a directional manner, and constructs an engineered probiotic compound EcN@BEVs. The nano-coated BEVs attached to the outer surface of the Escherichia coli Nissle 1917 EcN serve as a rigid barrier, enhances the resistance to gastric acid and bile salts, promotes long-term retention in the intestinal tract by improving adhesion to mucosal epithelium, and improves the survival rate of probiotics under various extreme conditions in the digestive tract, and effectively promotes the colonization ability of the probiotics in the intestinal tract. Due to the anti-inflammatory properties of the bletilla striata-derived nanoparticles and the high survival rate and strong intestinal adhesion ability of the encapsulated probiotics, the EcN@BEVs probiotic compound has a better treatment effect in treating intestinal inflammation than the uncoated EcN.

The invention belongs to the technical field of food microorganisms, and particularly relates to a high-activity probiotic microcapsule based on a metal-phenolic aldehyde network composite wall material as well as a preparation method and application of the high-activity probiotic microcapsule. The microcapsule prepared by the invention takes lactic acid bacteria and the like as a core material, and the core material is compounded with a fructo-oligosaccharide-mannitol composite protective agent; a five-layer structure of sodium alginate, chitosan, EGCG, a metal ion composite layer and konjac glucomannan is innovatively constructed for a wall material, a dense metal-phenolic network (MPN) is formed through coordination of EGCG and Ca < 2 + > / Fe < 3 + > / Zn < 2 + >, and a low-temperature pre-freezing-low-temperature electrostatic spray drying synergistic process is combined to prepare the composite material. The particle size of the obtained microcapsule is 120-160 microns, and the microcapsule is resistant to gastric acid and bile salt and high in survival rate, has the characteristics of oxidation resistance and intestinal adhesion enhancement, and can be widely applied to the fields of foods, functional fermented foods, health foods, medicines and the like.

The application discloses an application of a lysine-porphyrin conjugate LD4 in preparation of a photodynamic medicine for preventing or treating tissue adhesion, and belongs to the technical field of medical anti-adhesion medicines. The medicine is administered by local smearing or spraying on a surgical wound surface, and single photodynamic treatment is carried out under the condition of a wavelength of 650-660 nm, a power density of 20-50 mW / cm2 and a light irradiation dose of 10-60 J / cm2, so that active oxygen is generated, and the anti-adhesion effect is achieved by inhibiting the activation of fibroblasts into myofibroblasts, reducing the excessive synthesis and deposition of type I collagen and other mechanisms. Experiment proves that the application has a significant prevention effect on various postoperative tissue adhesions such as abdominal wall adhesion, intestinal adhesion and tendon adhesion, the adhesion score is reduced by more than 70%, the operation is simple, the safety is high, there is no obvious toxic and side effects, and the application has a wide clinical application prospect.

The invention belongs to the technical field of medicines, and particularly relates to a novel medical application of Danbai granules, in particular to an application of the Danbai granules in preparation of medicines for treating appendicitis and complications thereof. The Danbai granules can obviously inhibit inflammatory response of model rats with appendicitis caused by HCl, and can obviously relieve various symptoms of model rabbits with acute appendicitis. Besides, the Danbai granules are pure traditional Chinese medicine preparations, have no toxic or side effects, are non-traumatic treatment, can effectively relieve the pain of patients, have definite curative effects on infection after the appendix operation, intestinal adhesion after the operation, chronic appendicitis and the like, open up a new treatment approach for patients who are not resistant to the operation or fear of the operation, and have remarkable social benefits and economic benefits.

The present disclosure can improve the degree of soy protein proteolysis and the ability to produce valine, isoleucine, and leucine, which are branched-chain amino acids, as well as other amino acids, such as threonine, glycine, tyrosine, and lysine. Accordingly, the present disclosure can prevent sarcopenia and has antioxidant activity. Also, the present disclosure can maintain protein metabolic balance and relieve sarcopenia by muscle synthesis.The self-aggregation, hydrophobicity, and intestinal adhesion of a mixed strain is improved compared to a case where a single strain used for the mixed strain is used. Therefore, when the mixed strain of the present disclosure is ingested, the strain can remain for a long time in the intestine.